Adept AI vs Adaptyv Biosystems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Adept AI

EmergingAI Infra

AI Agents

Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.

About

Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.

Full profile

Adaptyv Biosystems

EmergingHealthcare

General

Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.5% to 13% testing 10K+ proteins for 30+ pharma/biotech partners competing with Recursion for AI drug discovery.

AI VisibilityBeta
Overall Score
D24
Category Rank
#995 of 1167
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
21
Perplexity
21
Gemini
29

About

Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.